Month: August 2022

Recon takes an analytical look behind select developments in healthcare

An auto- or allo- future for cell therapy?

Sarah Dolman and Maggie Pickard August 26, 2022

Download a PDF of this article here. Ex vivo gene-therapies have been a game-changer for aggressive hematologic cancers. These products can effectively cure patients who otherwise had very low chance of survival beyond 5 -years. However, making these products is exceptionally complex and the drugs are priced accordingly (from $370,000 to over $2.5M). While few patients receive these treatments today, clinical development could lead to a much broader population. If 1 in 20 newly diagnosed cancers were optimally treated with these high-price therapies, the cost to health-payers could become untenable

An innovative sales strategy for a pivotal drug; Novartis trailblazes with Leqvio

Thomas Uhler and Jason Brauner August 19, 2022

After the $9.7B acquisition of The Medicines Company two and a half years ago, Novartis is eager to demonstrate value with a successful launch of the primary target of the deal, Leqvio. This launch is also a key catalyst for new revenue generation at Novartis, due to a $9B patent cliff by 2026. Given the high-stakes nature of Leqvio’s launch, the decision of the Swiss pharma to employ a non-traditional sales strategy in several key countries, including US and England, is noteworthy. Novartis paves an innovative commercial path for

An excellent July vintage: an opinionated take on NEJM highlights for July 2022

Marc Herant August 1, 2022

Tirzepatide in pole position As previously described in this blog, GLP-1 agonists initially designed to treat glycemia in Type-2 diabetes are emerging as powerful weight loss agents in obesity independent of diabetic status. Recently, tirzepatide (Mounjaro, Lilly, approved May 2022) which combines GLP-1 and GIP activity has shown potential to be best in class, and this is supported by a 72-week study that randomized 2539 obese individuals to 3 different tirzepatide doses or placebo. The results are nothing short of spectacular with ~-21% mean change in weight at the optimal

Month: August 2022

Recon takes an analytical look behind select developments in healthcare

An auto- or allo- future for cell therapy?

An innovative sales strategy for a pivotal drug; Novartis trailblazes with Leqvio

An excellent July vintage: an opinionated take on NEJM highlights for July 2022

SUBSCRIBE

Categories

Authors

Archives